VDAC1 and fatty liver disease: CATR, an ANT1‐specific inhibitor that maintains ANT1 in c‐state to promote VDAC‐ANT1 complex formation, has been shown to play a protective role in hepatic steatosis and insulin resistance in mice (Cho et al, 2017).